Shire confirms talks with Barr to resolve Adderall XR patent dispute

08/19/2005 | Times (London) (subscription required), The

Shire Pharmaceuticals confirmed reports it met with Barr Laboratories to resolve a dispute over its patent for Adderall XR, for attention deficit disorder. Shire is defending the patent against a challenge by Barr, which wants to produce a generic version of Adderall XR, but Shire said it was looking at options for settling the issue, including continuing a court fight to defend the patent.

View Full Article in:

Times (London) (subscription required), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA